Unknown

Dataset Information

0

Applications of iPSC-derived beta cells from patients with diabetes.


ABSTRACT: Improved stem cell-derived pancreatic islet (SC-islet) differentiation protocols robustly generate insulin-secreting β cells from patient induced pluripotent stem cells (iPSCs). These advances are enabling in vitro disease modeling studies and the development of an autologous diabetes cell replacement therapy. SC-islet technology elucidates key features of human pancreas development and diabetes disease progression through the generation of pancreatic progenitors, endocrine progenitors, and β cells derived from diabetic and nondiabetic iPSCs. Combining disease modeling with gene editing and next-generation sequencing reveals the impact of diabetes-causing mutations and diabetic phenotypes on multiple islet cell types. In addition, the supply of SC-islets, containing β and other islet cell types, is unlimited, presenting an opportunity for personalized medicine and overcoming several disadvantages posed by donor islets. This review highlights relevant studies involving iPSC-β cells and progenitors, encompassing new conclusions involving cells from patients with diabetes and the therapeutic potential of iPSC-β cells.

SUBMITTER: Maxwell KG 

PROVIDER: S-EPMC8080107 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3696557 | biostudies-literature
| S-EPMC6294552 | biostudies-literature
| S-EPMC10253081 | biostudies-literature
| S-EPMC5500592 | biostudies-literature
| S-EPMC6551886 | biostudies-other
| S-EPMC4372110 | biostudies-other
| S-EPMC7542911 | biostudies-literature
| S-EPMC6942385 | biostudies-literature
| S-EPMC6068261 | biostudies-literature
| S-EPMC4665797 | biostudies-other